Combination therapy using a TNF binding protein for treating TNF-mediated diseases
AssigneeAmgen Inc.
InventorsAlison M. Bendele, Regina M. Sennello, Carl K. Edwards III
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating or preventing acute and/or septic shock. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and a Fas antigen. In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and a Fas antigen useful in such methods.
Claims8
A pharmaceutical composition comprising a TNF binding protein and a Fas antigen.
A method for treating septic shock which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein which is administered prior to, concurrently with or after administration of a Fas antigen.
Dependencies are inferred from the claim text.